Shares of Avadel Pharmaceuticals AVDL decreased 1.3% in pre-market trading after the company reported Q2 results.
Earnings per share increased 47.83% year over year to ($0.12), which missed the estimate of ($0.10).
Revenue of $10,091,000 declined by 42.51% year over year, which beat the estimate of $7,370,000.
Avadel Pharmaceuticals hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Aug 10, 2020
Time: 08:30 AM
ET Webcast URL: http://public.viavid.com/player/index.php?id=141026
Recent Stock Performance
Company's 52-week high was at $13.49
52-week low: $1.82
Price action over last quarter: down 9.64%
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.